AbbVie shows a pronounced decline in multi-year profitability: net income compounded at -29.1% a year (CAGR, or compound annual growth rate) over three years while revenue compounded at 1.8% a year. One recent annual net-income print is flagged as an extreme outlier and materially distorts the headline net-income CAGR, which understates the uncertainty in the underlying trend. Latest annual revenue rose 8.6% YoY (year-over-year) while net income fell 1.2% YoY, and the most recent quarter posted $3.61B in net income with a 419.9% QoQ (quarter-over-quarter) improvement. Assets exceed liabilities by the reported balance-sheet metrics and the Altman Z-score of 2.75 sits in the grey zone, where the model’s safe threshold is 2.99 and distress is 1.81. The Piotroski F-Score of 7 on a 0 to 9 quality scale indicates strong earnings-quality signals despite the earnings decline. With a price-to-earnings ratio near 120.5, the next report must show whether net income growth normalizes after the outlier or whether the decline persists.